COVID-19
Conditions
Brief summary
This study is a multi-center and open design, phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this study is to evaluate the safety of the SARS-CoV-2 Inactivated vaccine in population aged 3\ 17 years and in people with pre-existing disease to provide reference for improving the immunization strategy of COVID-19 vaccine.
Detailed description
This study is a multi-center and open design, phase Ⅳ clinical trial in population aged 3\ 17 years . The experimental vaccine will be manufactured by Sinovac Research and Development Co.,Ltd.The study is planned to be carried out in 11 provinces from August 2021 to December 2022, including Liaoning, Heilongjiang, Anhui, Fujian, Jiangxi, Hubei, Guangxi, Chongqing, Guizhou, Yunnan and Gansu. Each province will serve as a research center, and each research center will select the corresponding research site.A total of 33000 subjects including patients with pre-existing will be enrolled with 3000 for each research center, including 600 subjects aged 3\ 5years，1200 subjects aged 6\ 11 years,1200 subjects aged 12\ 17 years. And subjects will receive two doses of vaccine on day 0 and day 28.
Interventions
BIOLOGICALExperimental Group
SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
Sponsors
Sinovac Life Sciences Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 17 Years
Healthy volunteers
Yes
Inclusion criteria
* Have not received any COVID-19 vaccine in the past or at least one dose of CoronaVac manufactured by Sinovac Research and Development Co.,Ltd; * Population aged 3\ 17 years ; * The subjects can understand and voluntarily sign the informed consent form and participate in the follow-up;
Exclusion criteria
* History of severe allergy to the vaccine such as acute allergic reaction,angioedema and dyspnea ; * Severe neurological disease such as Myelitis transverse,Guillain-Barre Syndrome and demyelinating disorders; * Acute disease,acute onset of chronic disease and severe chronic diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety index 1-incidence of adverse reactions | Within 0~7 days after each dose | Incidence rate of adverse reactions within 0\ 7 days after each dose in all populations. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety index 2-incidence of adverse reactions | Within 0-28 days after each dose vaccination | Incidence rate of adverse reactions within 0\ 28 days after each dose in all populations |
| Safety index 3-incidence of adverse reactions | Within 0~7 days after each dose vaccination | Incidence of adverse reactions within 0\ 7 days after each dose in each age group |
| Safety index 4-incidence of adverse reactions | Within 0~28 days after each dose vaccination | Incidence rate of adverse reactions within 0\ 28 days after each dose in each age group |
| Safety index 5-incidence of adverse reactions | Within 0~7 days after each dose vaccination | Incidence of adverse reactions within 0\ 7 days after each dose in the population with pre-existing disease. |
| Safety index 6-incidence of adverse reactions | Within 0~28 days after each dose vaccination | Incidence of adverse reactions within 0\ 28 days after each dose in the population with pre-existing disease. |
Countries
China
Outcome results
None listed